HUMAN PAPILLOMAVIRUS

VACCINE
• The duration of protection conferred by 3 or 2 doses of HPV vaccines is still
unclear.
• However, data suggest that the duration of protection after 3 doses of vaccine will
be long lasting, with no evidence of loss of vaccine protection through 8–10 years
of follow-up
• Furthermore, it is unknown whether the duration of protection conferred by 2
doses will be similar to that of 3 doses.
• However, the 9-valent trial found that antibody titers at one month after the last
dose were noninferior and actually higher in the adolescents who received 2 doses
separated by 6 or 12 months, compared with the young adult women who received
the standard 3-dose schedule
• If 2-dose schedule of 9-valent vaccine provides at least 20 years of protection,
2-dose schedules would lead to substantial healthcare cost savings and
reductions in the burden of HPV-associated diseases, and 3-dose schedules
would be relatively cost-inefficient in comparison.
• On the other hand, if a 2-dose schedule provides <20 years of protection,
whereas 3 doses provide long-term protection (ie, >20 years), switching to a 2-
dose strategy would lead to substantial losses in population-level effectiveness.
• These conclusions are robust to plausible assumptions about HPV natural
history, initial vaccine efficacy following 2 and 3 doses, screening method,
burden of disease, and healthcare costs.
ASAM FOLAT VS FOLINIC ACID
ASAM FOLAT VS FOLINIC ACID
OVARIAN CANCER STAGING
OVARIAN CANCER STAGING
BORDERLINE OVARIAN TUMOR
ETIOLOGI CERVICAL CANCER
SCREENING CERVICAL CANCER